Advertisement
COR vs MCK
Which Stock Would AI Choose? Cencora (COR) vs. McKesson (MCK) Stock Comparison
Key Takeaways
- Cencora (COR) and McKesson (MCK) are leading pharmaceutical distributors, with MCK holding a larger market capitalization of approximately $99 billion compared to COR's $59 billion.
- COR has shown stronger year-to-date performance at +10.27%, outperforming MCK's +1.82%, though both have faced recent one-month declines around 5%.
- Valuation metrics differ notably, with MCK trading at a lower trailing P/E ratio of 23.20 versus COR's 36.32 (P/E means price-to-earnings ratio).
- Both stocks anticipate quarterly earnings reports in early May, with analysts projecting growth for each amid ongoing sector demand for pharmaceuticals.
- Recent analyst coverage, including William Blair's Outperform ratings, highlights competitive moats in healthcare distribution for both.
Introduction
This stock comparison examines COR and MCK, two dominant players in pharmaceutical wholesale distribution. As peers in the healthcare supply chain, they benefit from steady demand for drugs and medical supplies but face shared challenges like regulatory scrutiny and margin pressures. Traders seeking short-term momentum and investors focused on long-term sector stability will find value in analyzing their relative performance, valuations, and growth catalysts in the current market environment.
COR Overview and Recent Performance
Cencora, Inc. (COR) is a global leader in pharmaceutical sourcing and distribution, serving pharmacies, hospitals, and providers through U.S. and international segments that include specialty logistics and data analytics. In recent quarters, the company reported fiscal Q1 2026 revenue of $85.9 billion, up 5.5% year-over-year, with adjusted earnings per share (EPS) of $4.08, reflecting 9% growth despite a slight revenue miss. Shares have experienced volatility in recent weeks, declining about 5% over the past month amid broader market activity, though year-to-date gains stand at over 10%. Sentiment has been influenced by strategic expansions, such as acquisitions in patient services and retina operations, alongside anticipation for Q2 earnings expected around early May.
MCK Overview and Recent Performance
McKesson Corporation (MCK) delivers healthcare solutions via U.S. pharmaceutical distribution, prescription technology, medical-surgical supplies, and international operations. The company has demonstrated resilient growth, with recent quarterly results prompting upward revisions to fiscal 2026 adjusted EPS guidance to $37.10-$37.90. In recent market activity, shares have traded sideways to slightly down over the past month, with year-to-date returns at about 2%, reflecting steady demand in core distribution offset by sector rotations. Positive sentiment stems from analyst initiations like William Blair's Outperform rating, citing a durable competitive moat, and expectations for Q4 earnings growth in early May.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of 25 top-performing AI trading bots from over 350 available, each designed for diverse strategies across thousands of tickers. These bots showcase impressive stats, including annualized returns ranging from +23% to +162%, win rates of 51% to 88%, and profit factors up to 11.70, targeting sectors like semiconductors, industrials, and finance with varying timeframes from daily to multi-week holds. Traders can copy signals via virtual or brokerage agents for automated execution. Explore these high-potential options tailored to current market conditions to enhance your strategy.
Head-to-Head Comparison
Both COR and MCK thrive on pharmaceutical wholesale, but MCK offers broader diversification into technology solutions and medical-surgical distribution, potentially buffering distribution margin squeezes. Growth drivers include biosimilars adoption and specialty drug demand, though COR emphasizes international expansion. Recent momentum favors COR on YTD returns, but MCK shows relative stability with a lower beta of 0.35 versus 0.64. Risk factors like opioid litigation persist for both, while MCK's superior valuation (lower P/E) and scale provide a trade-off for growth-oriented investors eyeing COR.
Tickeron AI Verdict
Tickeron’s AI currently leans toward MCK based on trend consistency, attractive valuation metrics, and recent analyst support signaling stronger relative positioning amid healthcare sector dynamics. While COR exhibits higher YTD momentum and acquisition catalysts, MCK's scale and lower risk profile suggest higher probability of outperformance in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COR is a Buy and MCK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COR’s FA Score shows that 1 FA rating(s) are green whileMCK’s FA Score has 2 green FA rating(s).
- COR’s FA Score: 1 green, 4 red.
- MCK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COR’s TA Score shows that 4 TA indicator(s) are bullish while MCK’s TA Score has 5 bullish TA indicator(s).
- COR’s TA Score: 4 bullish, 4 bearish.
- MCK’s TA Score: 5 bullish, 3 bearish.
Price Growth
COR (@Medical Distributors) experienced а +2.41% price change this week, while MCK (@Medical Distributors) price change was +1.08% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +1.12%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was -6.17%.
Reported Earning Dates
COR is expected to report earnings on Aug 05, 2026.
MCK is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Medical Distributors (+1.12% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
| COR | MCK | COR / MCK | |
| Capitalization | 54.8B | 94.2B | 58% |
| EBITDA | 5.03B | 7.18B | 70% |
| Gain YTD | -16.269 | -4.233 | 384% |
| P/E Ratio | 21.58 | 20.43 | 106% |
| Revenue | 329B | 403B | 82% |
| Total Cash | 2.18B | 3.98B | 55% |
| Total Debt | 12.4B | 8.61B | 144% |
COR | MCK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 60 Fair valued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 35 | 21 | |
SMR RATING 1..100 | 11 | 100 | |
PRICE GROWTH RATING 1..100 | 60 | 57 | |
P/E GROWTH RATING 1..100 | 87 | 80 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MCK's Valuation (8) in the Medical Distributors industry is somewhat better than the same rating for COR (60) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew somewhat faster than COR’s over the last 12 months.
MCK's Profit vs Risk Rating (21) in the Medical Distributors industry is in the same range as COR (35) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew similarly to COR’s over the last 12 months.
COR's SMR Rating (11) in the Real Estate Investment Trusts industry is significantly better than the same rating for MCK (100) in the Medical Distributors industry. This means that COR’s stock grew significantly faster than MCK’s over the last 12 months.
MCK's Price Growth Rating (57) in the Medical Distributors industry is in the same range as COR (60) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew similarly to COR’s over the last 12 months.
MCK's P/E Growth Rating (80) in the Medical Distributors industry is in the same range as COR (87) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew similarly to COR’s over the last 12 months.
| COR | MCK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 64% | 3 days ago 71% |
| Stochastic ODDS (%) | 3 days ago 51% | 3 days ago 45% |
| Momentum ODDS (%) | 3 days ago 61% | 3 days ago 55% |
| MACD ODDS (%) | 3 days ago 62% | 3 days ago 71% |
| TrendWeek ODDS (%) | 3 days ago 62% | 3 days ago 64% |
| TrendMonth ODDS (%) | 3 days ago 63% | 3 days ago 67% |
| Advances ODDS (%) | 3 days ago 61% | 5 days ago 65% |
| Declines ODDS (%) | 19 days ago 42% | 3 days ago 42% |
| BollingerBands ODDS (%) | 3 days ago 48% | 5 days ago 76% |
| Aroon ODDS (%) | N/A | 3 days ago 26% |
Advertisement